Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Efficient Identification of miRNAs for Classification of Tumor Origin

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Molecular Characterization of the Danish Prion Diseases Cohort With Special Emphasis on Rare and Unique Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. EP1.08-07 Correlation Between Genetic Profiling and Response in Danish ALK-Positive NSCLC Patients Treated with Crizotinib

    Research output: Contribution to conferencePosterResearchpeer-review

  3. A Novel Eight Octapeptide Repeat Insertion in PRNP Causing Prion Disease in a Danish Family

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Iván Prieto-Potin
  • Clara Montagut
  • Beatriz Bellosillo
  • Matthew Evans
  • Matthew Smith
  • Linea Melchior
  • Werner Reiltin
  • Michael Bennett
  • Veronica Pennati
  • Francesca Castiglione
  • Karl-Friedrich Bürrig
  • Ulrike Cooper
  • Barbara Dockhorn-Dworniczak
  • Christiana Rossenbach
  • Claudia M Luna-Aguirre
  • Hugo A Barrera-Saldaña
  • José C Machado
  • José L Costa
  • Rinat Yacobi
  • Hilla Tabibian-Keissar
  • Simonetta Buglioni
  • Livia Ronchetti
  • Lotte Douglas-Berger
  • Hendrikus J Dubbink
  • Mohammed Alorini
  • Jean-Christophe Sabourin
  • Federico Rojo
View graph of relations

Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry-based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.

Original languageEnglish
JournalThe Journal of molecular diagnostics : JMD
Volume20
Issue number5
Pages (from-to)664-676
Number of pages13
ISSN1525-1578
DOIs
Publication statusPublished - Sep 2018

ID: 56538326